AIGH Capital Management’s ADC Therapeutics ADCT Stock Holding History

AIGH Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.28M	Buy	+4,324,327	New	+$5.06M	0.53%	31

Other funds holding ADCT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Sanibel Captiva Trust Company Sanibel, Florida $4.04B AUM 26.09% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Revolve Wealth Partners Hackensack, New Jersey $959M AUM 16.43% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

AIGH Capital Management's ADCT Position: Q3 2026 in Review

AIGH Capital Management opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 4,324,327 shares worth $5.28M. The stake represents 0.53% of the portfolio and ranks #31 among its holdings.

41 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

AIGH Capital Management held 4,324,327 shares of ADC Therapeutics worth $5.28M as of Q3 2026.
ADC Therapeutics was a new AIGH Capital Management position in Q3 2026.
ADC Therapeutics made up 0.53% of AIGH Capital Management's portfolio in Q3 2026, its #31 holding.
41 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on AIGH Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.